Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of BMS-986368 in Healthy, Elderly, and Japanese Participants
NCT06411730Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- May 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bms-986368 in Alzheimer's disease (AD) and multiple sclerosis (MS) (9 cohorts), sponsored by Celgene Corporation. Primary endpoints: Number of participants with adverse events (AEs) up to 44 days, Number of participants with serious adverse events (SAEs) up to 44 days and 4 more. Started May 2024; status: completed.
02
Drugs
bms-986368
03
Conditions
Alzheimer's disease (AD)multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06411730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06411730.